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Neurotrophins and their receptors of the Trk family play a critical role in prolife ation, differentiation and sur-
vival of the developing neurons. There are reports on their expression in neoplasms too, namely, the primitive 
neuroectodermal tumours of childhood, and in adult astrocytic gliomas. The involvement of Trk receptors in 
tumour pathogenesis, if any, is not known. With this end in view, the present study has examined 10 tumour 
biopsy samples (identified as astrocytoma, pilocytic astr c tom  and glioblastoma) and peritumoral brain tissue 
of adult patients, for the presence of Trk A and Trk B receptors, by immunohistochemistry. The nature of the 
tumour samples was also confirmed by their immunoreactivity (IR) to glial fibrillary acidic protein. In the 
peritumoral brain tissue, only neurons showed IR for Trk A and Trk B. On the contrary, in the tumour sections, 
the IR to both receptors was localized in the vast majority of glia and capillary endothelium. There was an 
obvious pattern of IR in these gliomas: high levels of IR were present in the low-grade (type I and II) 
astrocytoma; whereas in the advanced malignant forms (WHO grade IV giant cell glioblastoma and glio-
blastoma multiforme) the IR was very weak. These findings suggest that Trk A and Trk B are involved in 
tumour pathogenesis, especially in the early stage, and may r spond to signals that elicit glial proliferation, and 
thus contribute to progression towards malignancy. 
[Wadhwa S, Nag T C, Jindal A, Kushwaha R, Mahapatra A K and Sarkar C 2003 Expression of the neurotrophin rec ptors Trk A and  
Trk B in adult human astrocytoma and glioblastoma; J . Biosci. 28 181–188] 
1. Introduction 
The development as well as maintenance of the nervous 
system is critically dependent upon members of a family 
of neurotrophins. Various neurotrophins [nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), NT-4/5 and NT-6] are essential 
for the survival and maintenance of basal forebrain cho-
linergic neurons (NGF), dopaminergic striatal neurons 
and central GABAergic neurons (BDNF; Chao 1992; 
Barbacid 1994; Davies 1994; De la Rosa et l 1994; 
Bothwell 1995; Henderson 1996; Lewin and Barde 1996). 
Besides their role in neuronal development (Tucker et al 
2001), several lines of evidence suggest a possible thera-
peutic potential for neurotrophins in pathology of the 
nervous system. For instance, axotomy- and ischemia-
induced retinal changes in experimental animals can  
be delayed and transiently protected by intravitreal  
injections of NGF (Siliprandi et al 1993) and BDNF 
(Mansour-Roubaey et al 1994; Unoki and Lavail 1994). 
Neurotrophins mediate their various functions by binding 
to a low-affinity receptor, r75 NTR (common to all neuro-
trophins) as well as to specific high-affinity receptors of 
tyrosine kinase family (Trk). NGF binds to Trk A, BDNF 
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and NT-4/5 bind to Trk B and NT-3 binds to Trk C (Klein 
et al 1991; Lamballe et al 1991; Chao 1992; Barbacid 
1994). The binding of neurotrophins to their cognate rece-
ptors activates signal transduction by inducing autophos-
phorylation of the appropriate Trk receptors. 
 Studies have reported the expression of neurotrophin 
receptors in neuroblastoma, a type of pediatric tumou  of 
the central nervous system (Donovan et al 1994; Naka-
gawara et al 1994). Washiyama et al (1996) demonstra-
ted several neurotrophins as well as their receptors in 
medulloblastoma and other primitive neuroectodermal 
tumours of children. Trk receptors are expressed at high 
levels in these tumours, and the clinical significance 
thereof is suggested to be predictive of a favourable out-
come (Segal et al 1994; Brodeur et al 1997; Dominici  
et al 1997). The available evidence tends to suggest that 
the Trk receptors greatly influence the clinical behaviour 
of the neoplasms. 
 Earlier, Wang etal (1998) had examined Trk A, Trk B 
and Trk C expression in 34 astrocytic tumours of diffe-
rent grades. We have conducted a similar study on exam-
ining the expression of Trk A and Trk B in adult human 
astrocytoma and noted that there is a clear difference in 
their pattern of expressions in early, benign to advanced 
malignant stages, not highlighted by them. Hence, this 
paper reports on the pattern of immunoreactivity to Trk A 
and Trk B receptors in adult astrocytoma and glioblas-
toma in surgical specimens. 
2. Material and methods 
2.1 Sample collection 
Tumour tissues were obtained at surgery from 10 patients 
admitted to the Neurosurgery Department, All India Insti-
tute of Medical Sciences, New Delhi, for clinical treat-
ment. Samples were taken from the main bulk of the 
tumours and the peritumoral region, which had to be exci-
sed during removal of the tumours. As diagnosed and 
confirmed by the surgeons, the peritumoral brain regions 
were without oedema or gross neuropathological changes. 
Details of the tumour types examined are summarized in 
table 1. Diagnosis as well as grading of the tumours was 
confirmed following the WHO classifiction (Kleihues  
et al 1993) by histological staining of sections with hema-
toxylin and eosin (H & E), and also by immunohistoche-
mical staining for glial fibrillary acidic protein (GFAP).
2.2 Tissue fixation 
All tissue materials were fixed in 4% paraformaldehyde 
for 24 h at 4°C. After rinsing, tissues were cryoprotected 
in 15% to 30% sucrose overnight and embedded in OCT 
compound (Miles, Elkhart, IN, USA). Frozen sections of 
18–20 mm thickness were cut, serially collected in vials 
containing phosphate buffer (pH 7×4) and stored at 4°C 
ntil use. Adjacent sections (12 mm thickness) were moun-
ted onto gelatin-coated slides and stained with H & E. 
2.3 Antibodies 
The Trk-receptor antibodies employed in this study were 
obtained from Santa Cruz Biotechnology, Inc. (Cali-
fornia, USA). These were affinity-purified rabbit poly-
clonal antisera raised against (i) a peptide corresponding 
to 763–777 amino acid residues at the C-terminal domain 
of human Trk A (SC-118), and (ii) a peptide correspond-
ing to 794–808 residues at the C-t rminus of mouse Trk 
B (SC-12). Control peptides (SC-118P and 12P) were 
also procured from the same source. Both antibodies  
recognize the full-length isoforms of Trk receptors and 
the catalytic intracellular tyrosine kinase domain. Accord-
ing to the manufacturer, Trk A and Trk B receptor anti-
bodies do not cross-react with each other, as determined 
by Western blot analysis. 
2.4 Immunohistochemistry 
Sections were initially treated with 0×3% hydrogen pero-
xide in 80% methanol to quench endogenous peroxidase 
activity. After repeated washing, these were incubated in 
10% goat normal serum to block non-specific reactions. 
This was followed by incubation with the primary anti-
bodies (dilution 1 : 2000) to Trk A and Trk B receptors 
for 48 h at 4°C. The secondary antibody used was bio-
tinylated goat anti-rabbit IgG (Vector Laboratories,  
Burlingame, California, USA; 1 : 200 dilution, 6 h at 4°C).  
After washing, sections were put in avidin-biot n-pero 
xidase complex (Vector Laboratories; dilution 1 : 200)  
Table 1. Details of the tumour samples examined. 
        
Case 
No. 
Age 
(year) 
 
Sex 
 
Tumour type and grade         
 1 15 M Pilocytic astrocytoma II (cerebellar) 
 2 28 M Protoplasmic astrocytoma II 
 3 32 M Protoplasmic astrocytoma I 
 4 28 M Pilocytic astrocytoma I (third ventricl ) 
 5 35 M Astrocytoma II 
 6 31 F Giant cell glioblastoma IV 
 7 50 F Glioblastoma multiforme IV 
 8 48 M Glioblastoma multiforme IV 
 9 40 M Glioblastoma multiforme IV 
10 50 M Giant cell glioblastoma IV 
        
M, male; F, female. 
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for 3 h at room temperature. For visualization, secti s
were treated in 0×03% diaminobenzidine tetrahydrochlo-
ride (DAB) in 0×1 M acetate-imidazole buffer (pH 7×4) 
containing 0×5% nickel sulphate (as intensifier). Finally, 
sections were rinsed in water, mounted onto gelatin-
coated slides, dehydrated in ethanol, cleared and covered 
with DPX mountant. 
 For immmunolabelling with GFAP, sections were in-
cubated in a monoclonal mouse primary antiserum (Sigma 
Chemicals Co., St. Louis, MO, USA, catalog number G 
3893, dilution 1 : 200) for 48 h, followed by incubation 
in biotinylated anti-mouse IgG (Vector Laboratories; 1 : 
200 dilution, 6 h). The remaining procedure was identical, 
as outlined above. 
 As control, sections were incubated either without pri-
mary antisera or in the respective primary antisera preab-
sorbed with the control peptides (1 : 500) and then pro-
cessed from the secondary antibody step onward, as 
described above. 
 Intensity levels of Trk immunoreactivity noted in indi-
vidual tumour types were determined semiquantitatively 
with a four-point scale, where ‘1 ® 4’ denoted very weak 
to strong labelling, and are shown in table 2. 
3. Results 
In the apparently ‘normal tissues’ of peritumoral region, 
the immunoreactivity to Trk A and Trk B receptors was 
present in neurons only (figure 1b). Blood capillaries 
were nonreactive (figure 1c). 
 The pattern of Trk receptor immunoreactivity in indi-
vidual tumour types is described below. 
3.1 Astrocytoma (grade I and II) 
These were low-grade tumours of the temporal cortex. In 
grade I protoplasmic astrocytoma, there were characteris-
tic microcystic changes of the tissue, with swollen cyto-
plasm and moderate cellularity. No mitoses were seen. 
There was more cellularity in grade II tumours (figure 
1d) with little endothelial proliferation. In the surround-
ing peritumoral tissue, cellularity (neuronal as well as 
glial) was low (figure 1a, b). GFAP immunoreactivity was 
present predominantly in astrocytic processes in normal 
tissues, whereas within the tumour, immunoreactivity 
was seen only in glial cell bodies (not shown).
 In both grades of astrocytomas, there was high expres-
sion of Trk A and Trk B receptors (figure 1e, f; grade II 
astrocytoma, table 2) in glial cells. In grade II forms, the 
endothelium of tumour capillaries showed conspicuous 
immunoreactivity (figure 1e, f). This immunoreactivity 
was considered to be positive, since parallel sections 
treat d with DAB alone (the DAB reaction for peroxi-
dase) revealed no staining in tumour vasculature. 
3.2 Pilocytic astrocytoma (grade I and II) 
The grade I pilocytic astrocytoma was a tumour (figure 
2a) from the cerebellar vermis, the grade II form was 
from the cortex near the third ventricle. In both cases, 
there was moderate cellularity, and some endothelial pro-
liferation was present in the grade II tumour. GFAP immu-
noreactivity revealed the presence of abundant fi rils d 
elongated cells within the tumours (figure 2b; grade I). In 
both tumours, Trk A and B expression was the strongest 
amongst all tumour types examined (figure 2c, d; grade I, 
table 2). Immunoreactivity for both receptors was wide-
spread in the majority of the tumour cells, while only Trk 
A was strongly expressed in the tumour vessels in grade 
II forms (figure 2c). No staining was observed in the cap-
illaries of adjacent peritumoral brain tissue. 
3.3 Giant cell glioblastoma (WHO grade IV) 
In this highly malignant tumour type, there were frequent 
mitoses, some giant multinucleated cells with abundant 
cytoplasm and many small tumour cells (figure 3a). In 
the adjacent peritumoral ‘normal tissues’, GFAP immu-
noreactivity was present in many astrocytes and their 
processes (figure 3b). Within the tumour, fewer GFAP-
positive glial cells were seen (figure 3c), suggesting the 
undifferentiated nature of the glioma. Immunoreactivity 
for both Trk receptors was low in this tumour. The tumour 
cells were only occasionally and rather faintly stained 
(figure 3d, e; table 2). 
3.4 Glioblastoma multiforme (WHO grade IV) 
In this highly malignant tumour form, there was high 
cellularity and the cells were pleiomorphic. Necrosis was  
Table 2. Intensity of Trk receptor immunoreactivity  
in tumour samples examined.     
 Intensity 
      
Tumour type Trk A Trk B 
      
Pilocytic astrocytoma I 4+ 4+ 
Pilocytic astrocytoma II 4+ 4+ 
Protoplasmic astrocytoma I  3+ 3+ 
Protoplasmic astrocytoma II 3+ 4+ 
Astrocytoma II 3+ 4+ 
Giant cell glioblastoma IV 1+ 1+ 
Giant cell glioblastoma IV 1+ 1+ 
Glioblastoma multiforme IV 1+ 1+ 
Glioblastoma multiforme IV 1+ 1+ 
Glioblastoma multiforme IV 1+ 1+       
1+, Very weak; 2+, weak; 3+, moderate; 4+, strong or high. 
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Figure 1. Trk receptor immunoreactivity in different samples of astrocytomas and adjacent peritumoral ‘normal tissues’. (a–c) 
From peritumoral tissue adjacent to astrocytoma II, case No. 5: (a) H & E stained, showing few cellular elements; (b, c) showing 
Trk A and Trk B immunoreactivity, respectively. Neuronal nuclei are immunopositive (arrowheads in b); the arrow in (c) indicates 
a blood vessel without staining; (d–f) From astrocytoma II, case No. 5: (d) H & E stained, showing high cellularity in the tumour 
tissue; (e, f) showing Trk A and Trk B immunoreactivity, respectively in this glioma. The arrows indicate staining in the capillary 
endothelium. (g–i) From glioblastoma multiforme (grade IV, case No. 8): (g) H & E-stained tumour tissue showing necrosis with 
lymphocytic infiltration (asterisk) and moderate cellularity; (h, i) showing Trk A and Trk B immunoreactivity, respectively. In both 
cases staining intensity is weak (1+, table 2). Scale bar, 50 mm. 
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evident over a large area within the tumour (figure 1g) 
and there was marked proliferation of blood vessels. As 
in the giant cell glioblastoma, the cellular elements of this 
tumour showed very weak immunoreactivity (figure 1h, i). 
Capillary endothelium was also faintly stained. Control sec-
tions treated with the primary antisera preabsorbed with 
respective control peptides did not show any staini g 
(figure 2e, f). Also omission of the primary antisera did 
not reveal any staining in the tumour sections (figure 3f). 
4. Discussion 
Previous reports have shown that neurotrophins as well 
as their cognate receptors are expressed predominantly in 
the developing nervous system. Physiologically speaking, 
a given neuron does not express a growth-fact r receptor 
until it is ready for interaction with its ligand (Yan and 
Johnson 1998). However, information about the distri-
bution and possible role of neurotrophin receptors on glia 
is somewhat limited (Althaus et al 1992; Jelsma et al 
1993; Barres et al 1994; Ikeda and Puro 1994). A trun-
cated form of Trk B is reported to be expressed in glia of 
white matter (e.g. optic nerve), wherein the full-length 
form of Trk B, being involved in cell proliferation and/or 
differentiation, does not express (Klein etal 1990; Merlio 
et al 1992; Jelsma et al 1993). Under normal physio-
logical conditions, the glial cells do not express NGF 
receptors; however, in response to injury, the oligoden-
 
Figure 2. Pilocytic astrocytoma, case No. 1. (a) H & E-stained tumour showing moderate cellularity. (b) GFAP immunoreactivity 
in the adjacent tumour section. The abundant fibrils (arrows) are characteristic to this tumour. (c, d) Showing Trk A and Trk B im-
munoreactivity in the tumour cells respectively. The tumour vessels are strongly positive for Trk A (c, arrows). (e, f) Control sec-
tions treated with primary antibodies preabsorbed with respective control peptides, showing no staining for Trk A (e) and Trk B (f). 
Scale bar, 50 mm. 
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drocytes express NGF receptor (Althaus et al 1992). 
Hunton et al (1992) showed the presence of mRNAs for 
NGF receptors (p75 and Trk A) and Trk B in rat C6 
glioma cells. Here we report the predominant expression 
of Trk A and Trk B in adult human astrocytic tumours, 
especially in the benign state. It is possible that both  
receptors, by interacting with their neurotrophin ligands, 
may mediate glial proliferation in early astrocytoma. 
 In childhood neuroblastoma, there are reports on the 
expression of Trk A as well as p75-neurotrophin receptor 
(Donovan et al 1993; Nakagawara et l 1993; Dominici 
et al 1997). Trk A expression is high in the majority of 
neuroblastoma cases studied, especially in non-advanced 
stages (Borrelo et al 1993; Nakagawara et al 1993; 
Dominici et al 1997), and this has been associated with  
a favourable outcome (Kogner et al 1993; Nakagwara  
et al 1993). On the other hand, in aggressive, high-risk
neuroblastoma there is a lack of Trk A expression, though 
Trk B expression therein has been reported (Brodeur et al 
1997). The expression of Trk B in neuroblastoma is  
most probably related to tumour behaviour and outcome 
(Nakagawara et al 1994; Brodeur 1995; Brodeur et al 
1997). 
 In pediatric medulloblastoma, there are reports sugge-
sting involvement of several neurotrophins and their cog-
nate receptors in tumour pathogenesis (Keles et al 1993; 
Washiyama et al 1996). However, unlike Trk A, which is 
expressed predominantly in neuroblastoma, as already 
mentioned, Trk B (and also Trk C) expression in medul-
loblastoma appears to be characteristic (Washiyama et al 
1996). The present study shows that Trk A as well as Trk 
B is expressed at high levels in low grade astrocytoma, as 
also reported by Wang et al (1998). We believe that this 
overexpression might contribute to the progression of 
early neoplasms. On the contrary, in advanced, highly 
malignant forms of these tumours, there is an apparent 
 
Figure 3. Giant cell glioblastoma, grade IV, case No. 6. (a) H & E-stained tumour showing small tumour cells and some giant 
cells (arrowheads). (b  Adjacent peritumoral tissue, showing GFAP immunoreactivity in normal astrocytic processes (arrow). (c) 
From the tumour tissue. GFAP immunoreactivity is present in few glial cells (arrow) and their processes. (d, e) Showing weak 
staining (arrows) for Trk A and Trk B, in this malignant tumour respectively (see table 2). (f) Control tumour section (case No. 5) 
processed without primary antiserum (Trk A) treatment. No staining is present in tumour cells or capillaries. Scale bar, 50 mm. 
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downregulation of both Trk receptors. However, this was 
not reported by Wang et al (1998). Our findings bear 
similarity to the cases of aggressive neuroblastoma stu-
died by Brodeur (1995), in which there was a reported 
lack of Trk A and Trk C expression. Thus there appears 
to be a strong correlation between expression of Trk rece-
ptors and malignancy of tumours (neuroblastoma and astro-
cytoma); the more malignant the tumour, the lower the 
level of Trk expression. The reason for this apparent  
receptor downregulation at advanced stages of the tumours
is not clear. However, it does appear that the tumour cells 
become less responsive to the available neurotrophins 
during malignancy, to lead to growth factor-independent 
proliferation. 
 Trk receptors are expressed also in non-neuronal tissues 
too, e.g. kidney (Ernfors et al 1991; Durbeej t al 1993) 
and in pediatric renal neoplasms, as in Wilms’ Tumour 
(Donovan et al 1994). In our study, an interesting finding 
hitherto unknown and not rep rted by Wang et al (1998) 
is the localization of Trk immunoreactivity in capillaries 
of grade II tumours. It is possible that Trk receptors may 
mediate endothelial proliferation in early stages of the 
astrocytoma, but seemingly play no role in this process n
the advanced malignant forms. 
 In summary, this study reports the expression of Trk A 
and Trk B in adult human astrocytoma and glioblastoma, 
suggesting a role for these receptors in glial and endo-
thelial proliferation, especially in early stages of the neo-
plasms. 
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